UK markets closed

TC Biopharm (Holdings) Plc (TCBP)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
0.3784+0.0105 (+2.85%)
As of 11:49AM EST. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) 3.44M
Enterprise value 3.96M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)0.21
Price/book (mrq)1.35
Enterprise value/revenue 1.39
Enterprise value/EBITDA -3.33

Trading information

Stock price history

Beta (5Y monthly) N/A
52-week change 3-99.24%
S&P500 52-week change 312.18%
52-week high 396.1000
52-week low 30.3200
50-day moving average 33.0851
200-day moving average 311.2974

Share statistics

Avg vol (3-month) 3439.99k
Avg vol (10-day) 32.23M
Shares outstanding 59.36M
Implied shares outstanding 69.36M
Float 85.56M
% held by insiders 111.74%
% held by institutions 15.23%
Shares short (14 Nov 2023) 425.77k
Short ratio (14 Nov 2023) 40.05
Short % of float (14 Nov 2023) 40.29%
Short % of shares outstanding (14 Nov 2023) 40.28%
Shares short (prior month 12 Oct 2023) 4185k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 21:10
Last split date 312 Nov 2023

Financial highlights

Currency in GBP.

Fiscal year

Fiscal year ends 30 Dec 2022
Most-recent quarter (mrq)29 Jun 2023


Profit margin -54.24%
Operating margin (ttm)-409.33%

Management effectiveness

Return on assets (ttm)-67.01%
Return on equity (ttm)-102.37%

Income statement

Revenue (ttm)2.86M
Revenue per share (ttm)1.48
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)3.84M
EBITDA -10.98M
Net income avi to common (ttm)-1.55M
Diluted EPS (ttm)-3.5900
Quarterly earnings growth (yoy)-31.00%

Balance sheet

Total cash (mrq)1.92M
Total cash per share (mrq)0.33
Total debt (mrq)2.45M
Total debt/equity (mrq)122.09%
Current ratio (mrq)1.09
Book value per share (mrq)0.35

Cash flow statement

Operating cash flow (ttm)-12.19M
Levered free cash flow (ttm)-9.9M